New migraine use for Botox could be worth $1B

The FDA finally approved Allergan wrinkle-fighter Botox as a treatment for migraines.
Allergan has done it. The FDA finally approved its wrinkle-fighter Botox as a treatment for migraines. The new indication could add $1 billion to its current annual sales of $1.3 billion, analysts say. "This is the most meaningful market expansion that the product has had since it was approved for cosmetic use," Piper Jaffray's David Amsellem tells Bloomberg.
The new indication is specifically for patients with chronic migraines; that amounts to about 3.2 million people in the U.S. "This condition can greatly affect family, work, and social life, so it is important to have a variety of effective treatment options available," the FDA's Russell Katz says in a statement.
The expanded approval comes on the heels of an off-label marketing settlement between Allergan and the feds, in which the company agreed to pay $600 million to resolve claims that it had pushed Botox for unapproved uses--including migraine. And some aren't convinced that the evidence supports broad use
Related News
-
News Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners. -
News Updated: CPHI North America 2022 Blog
Follow along for live updates from CPHI North America, taking place in Philadelphia, PA from May 17-19. -
News Greater standardisation needed for effective ESG reporting - Expert panel
Increased transparency and standardisation in ESG reporting frameworks is emerging as a key requirement for investors. -
News MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space. -
News Pharmapack Awards 2022: Winners Revealed
The jury assessed a wide range of industry-changing innovations in packaging and drug delivery, ultimately selecting seven winners. -
News What it means to be 'At the heart of Pharma'
Informa Markets colleagues explain the motivations behind CPHI’s rebrand. -
News CPhI Podcast Series: Leveraging data science for sustainable autoinjector development
Environmental impact is an area of increasing focus for the pharma and biopharma industries, with companies like Merck, Pfizer and GlaxoSmithKline setting ambitious targets for carbon neutrality and laying plans for waste reduction. -
News Thermo Fisher and Charles River join consortium using robotics to produce cell therapies at scale
The Consortium aims to increase the scale of cell therapy manufacturing to a level impossible with current manual processes.
Position your company at the heart of the global Pharma industry with a CPhI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPhI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance